A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)
Titel:
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)
Auteur:
Daugaard, G. Skoneczna, I. Aass, N. De Wit, R. De Santis, M. Dumez, H. Marreaud, S. Collette, L. Lluch, J.R.G. Bokemeyer, C. Schmoll, H.J.